211 related articles for article (PubMed ID: 31534013)
1. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Riches LC; Trinidad AG; Hughes G; Jones GN; Hughes AM; Thomason AG; Gavine P; Cui A; Ling S; Stott J; Clark R; Peel S; Gill P; Goodwin LM; Smith A; Pike KG; Barlaam B; Pass M; O'Connor MJ; Smith G; Cadogan EB
Mol Cancer Ther; 2020 Jan; 19(1):13-25. PubMed ID: 31534013
[TBL] [Abstract][Full Text] [Related]
2. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
4. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
[TBL] [Abstract][Full Text] [Related]
5. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
8. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG
Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718
[TBL] [Abstract][Full Text] [Related]
9. Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.
Gill SJ; Wijnhoven PWG; Fok JHL; Lloyd RL; Cairns J; Armenia J; Nikkilä J; Lau A; Bakkenist CJ; Galbraith SM; Vens C; O'Connor MJ
Mol Cancer Ther; 2021 Sep; 20(9):1614-1626. PubMed ID: 34158341
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
[TBL] [Abstract][Full Text] [Related]
11. Methylation of
Li H; Yang W; Zhang M; He T; Zhou F; G Herman J; Hu L; Guo M
Epigenomics; 2021 Sep; 13(17):1403-1419. PubMed ID: 34558311
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts.
Scheper J; Hildebrand LS; Faulhaber EM; Deloch L; Gaipl US; Symank J; Fietkau R; Distel LV; Hecht M; Jost T
Strahlenther Onkol; 2023 Dec; 199(12):1128-1139. PubMed ID: 36229655
[TBL] [Abstract][Full Text] [Related]
13. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
Davis SL; Hartman SJ; Bagby SM; Schlaepfer M; Yacob BW; Tse T; Simmons DM; Diamond JR; Lieu CH; Leal AD; Cadogan EB; Hughes GD; Durant ST; Messersmith WA; Pitts TM
BMC Cancer; 2022 Oct; 22(1):1107. PubMed ID: 36309653
[TBL] [Abstract][Full Text] [Related]
14. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
15. Olaparib nanoparticles potentiated radiosensitization effects on lung cancer.
Wu M; Liu J; Hu C; Li D; Yang J; Wu Z; Yang L; Chen Y; Fu S; Wu J
Int J Nanomedicine; 2018; 13():8461-8472. PubMed ID: 30587971
[TBL] [Abstract][Full Text] [Related]
16. The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
Pike KG; Barlaam B; Cadogan E; Campbell A; Chen Y; Colclough N; Davies NL; de-Almeida C; Degorce SL; Didelot M; Dishington A; Ducray R; Durant ST; Hassall LA; Holmes J; Hughes GD; MacFaul PA; Mulholland KR; McGuire TM; Ouvry G; Pass M; Robb G; Stratton N; Wang Z; Wilson J; Zhai B; Zhao K; Al-Huniti N
J Med Chem; 2018 May; 61(9):3823-3841. PubMed ID: 29683659
[TBL] [Abstract][Full Text] [Related]
17. The effect of the ATM inhibitor AZD0156 on the radiosensitivity of human breast cancer and lung fibroblast cells.
Yilmaz U; Kamer D; Asik A; Kara HG; Gündüz C; Kamer S
J Cancer Res Ther; 2023; 19(2):203-207. PubMed ID: 37006058
[TBL] [Abstract][Full Text] [Related]
18. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
19. Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response.
Min A; Jang H; Kim S; Lee KH; Kim DK; Suh KJ; Yang Y; Elvin P; O'Connor MJ; Im SA
Mol Cancer Ther; 2018 Dec; 17(12):2507-2518. PubMed ID: 30232143
[TBL] [Abstract][Full Text] [Related]
20. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
Koneru B; Farooqi A; Nguyen TH; Chen WH; Hindle A; Eslinger C; Makena MR; Burrow TA; Wilson J; Smith A; Pilla Reddy V; Cadogan E; Durant ST; Reynolds CP
Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
